Antidepressant augmentation with raloxifene [5]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 1, 2005, Pages 96-98

  Grigoriadis, Sophie ^a   Kennedy, Sidney H ^a   Srinivisan, Janaki ^a   McIntyre, Roger S ^a   Fulton, Kari ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESTRADIOL; FOLLITROPIN; LIVER ENZYME; LUTEINIZING HORMONE; NEFAZODONE; PAROXETINE; PROGESTERONE; RALOXIFENE; SERTRALINE; VENLAFAXINE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HAMILTON SCALE; HUMAN; LETTER; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR DEPRESSION; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; QUESTIONNAIRE; REMISSION; TREATMENT OUTCOME;

AFFECT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 12344303957     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000150230.07243.52     Document Type: Letter

References (20)

1. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97-106.
2. Schneider LS, Small GW, Clary C. Estrogen replacement therapy and antidepressant response to sertraline. Am J Geriatr Psychiatry. 2001;9:393-399.
3. Rasgon NL, Altshuler LL, Fairbanks LA, et al. Estrogen replacement in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63(suppl 7):45-48.
4. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11-17.
5. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:49-57.
6. Greendale G, Reboussin B, Hogan P, et al. Symptom relief and side effects of postmenopausal hormone: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982-988.
7. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:58-66.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
9. North American Menopause Society (NAMS). A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of the North American Menopause Society. Menopause. 2000;7:76-86.
10. Grossman LD. Raloxifene: a review. J SOGC. 2000;22:3-10.
11. Strickler R, Stovall DW, Merritt D, et al. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo controlled randomized trial. Obstet Gynecol. 2000;96:359-365.
12. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl Med. 2001;334:1207-1213.
13. Nickelson T, Lufkin EG, Riggs RL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology. 1999;24:115-128.
14. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742-747.
15. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depressed patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174-180.
16. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183(2):414-420.
17. Jarcova NB, Martenyi F, Masanauskaite D, et al. Mood effect of raloxifene in postmenopausal women. Maturitas. 2002;42:71-75.
18. Bethea CL, Mirkes SJ, Su A, et al. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology. 2002;27:431-445.
19. Florio B, Quirici B, Casarosa E, et al. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women. Gynecol Endocrinol. 2001;15:359-366.
20. Soares CN, Almeida OP, Joffee H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen Psychiatry. 2001;58:529-534.